TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)
A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cy...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2017-10-01
|
Series: | Onkogematologiâ |
Subjects: | |
Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/257 |
id |
doaj-ccbc7c4b11d244ae8ba5dbc2e2e7d0c0 |
---|---|
record_format |
Article |
spelling |
doaj-ccbc7c4b11d244ae8ba5dbc2e2e7d0c02021-07-29T09:03:06ZrusABV-pressOnkogematologiâ1818-83462017-10-01123414910.17650/1818-8346-2017-12-3-41-49246TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)K. I. Zarubina0E. N. Parovichnikova1O. A. Gavrilina2A. N. Sokolov3V. V. Troitskaya4L. A. Kuzmina5V. E. Mamonov6G. M. Galstyan7V. G. Savchenko8National Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaNational Research Center for Hematology, Ministry of Health of RussiaA wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors.https://oncohematology.abvpress.ru/ongm/article/view/257ph-positive acute lymphoblastic leukemiatyrosine kinase inhibitorsselectivitycombined toxicityt315i mutationimatinibnilotinibdasatinibaxitinibponatinibblinatumomab |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
K. I. Zarubina E. N. Parovichnikova O. A. Gavrilina A. N. Sokolov V. V. Troitskaya L. A. Kuzmina V. E. Mamonov G. M. Galstyan V. G. Savchenko |
spellingShingle |
K. I. Zarubina E. N. Parovichnikova O. A. Gavrilina A. N. Sokolov V. V. Troitskaya L. A. Kuzmina V. E. Mamonov G. M. Galstyan V. G. Savchenko TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW) Onkogematologiâ ph-positive acute lymphoblastic leukemia tyrosine kinase inhibitors selectivity combined toxicity t315i mutation imatinib nilotinib dasatinib axitinib ponatinib blinatumomab |
author_facet |
K. I. Zarubina E. N. Parovichnikova O. A. Gavrilina A. N. Sokolov V. V. Troitskaya L. A. Kuzmina V. E. Mamonov G. M. Galstyan V. G. Savchenko |
author_sort |
K. I. Zarubina |
title |
TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW) |
title_short |
TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW) |
title_full |
TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW) |
title_fullStr |
TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW) |
title_full_unstemmed |
TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW) |
title_sort |
toxicity and efficacy of tyrosine kinase inhibitors in combination with chemotherapy in patient with resistant ph-positive acute lymphoblastic leukemia (case report and literature review) |
publisher |
ABV-press |
series |
Onkogematologiâ |
issn |
1818-8346 |
publishDate |
2017-10-01 |
description |
A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors. |
topic |
ph-positive acute lymphoblastic leukemia tyrosine kinase inhibitors selectivity combined toxicity t315i mutation imatinib nilotinib dasatinib axitinib ponatinib blinatumomab |
url |
https://oncohematology.abvpress.ru/ongm/article/view/257 |
work_keys_str_mv |
AT kizarubina toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT enparovichnikova toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT oagavrilina toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT ansokolov toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT vvtroitskaya toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT lakuzmina toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT vemamonov toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT gmgalstyan toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview AT vgsavchenko toxicityandefficacyoftyrosinekinaseinhibitorsincombinationwithchemotherapyinpatientwithresistantphpositiveacutelymphoblasticleukemiacasereportandliteraturereview |
_version_ |
1721249561546063872 |